3-溴-4-甲氧基吡啶 | 82257-09-8

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-溴-4-甲氧基吡啶
• 英文名称: 3-bromo-4-methoxypyridine
• 英文别名: 3-Brom-4-methoxypyridin
• CAS: 82257-09-8
• 化学式: C₆H₆BrNO
• 分子量: 188.024
• InChiKey: DSFJKFHIMBVWAV-UHFFFAOYSA-N

物化性质

• 沸点：
  214.5±20.0 °C(Predicted)
• 密度：
  1.530±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S39
• 危险类别码：
  R22,R37/38,R41
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-4-methoxypyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-4-methoxypyridine
CAS number: 82257-09-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H6BrNO
Molecular weight: 188

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-4-甲氧基吡啶 在 四(三苯基膦)钯 、 硫酸 、 palladium 10% on activated carbon 、 氨 、 氢溴酸 、 氢气 、 溴 、 硝酸 、 铁粉 、 potassium carbonate 、 氯化铵 、 三乙胺 、 间氯过氧苯甲酸 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， -20.0~100.0 ℃ 、400.01 kPa 条件下， 反应 146.5h， 生成 2-(2-Bromo-5-propan-2-ylpyridin-4-yl)sulfanylacetonitrile
  参考文献：
  名称：

  EP3712144

  摘要：

  公开号：
• 作为产物：
  描述：

  4-甲氧基吡啶 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 反应 120.0h， 以15%的产率得到3-溴-4-甲氧基吡啶
  参考文献：
  名称：

  N-溴代琥珀酰亚胺对活化吡啶的轻度区域选择性卤化

  摘要：

  已经研究了氨基、羟基和甲氧基吡啶（2-、3-和 4-取代）以及 2,6-二甲氧基吡啶与 N-溴代琥珀酰亚胺在不同溶剂中的区域选择性单卤化和二卤化反应。底物的反应性按氨基>羟基>甲氧基的顺序降低，区域选择性取决于取代基的位置（2-取代> 3-取代）。在大多数情况下，我们以区域选择性和高产率获得单溴化衍生物。羟基和氨基吡啶也可以用 2 当量的 NBS 以几乎定量的产率进行二溴化。

  DOI：

  10.1055/s-2001-18070

文献信息

• NAPHTHYRIDINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282328A1

  公开（公告）日：2018-10-04

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019148132A1

  公开（公告）日：2019-08-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• [EN] HETEROARYLBENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLBENZIMIDAZOLE
  申请人：BAYER PHARMA AG

  公开号：WO2017102091A1

  公开（公告）日：2017-06-22

  The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式（I）中的杂环芳基苯并咪唑化合物，其中R1、R2、R3、R4和R5如本文所定义，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖和/或炎症性疾病的药物组合物，作为唯一活性成分或与其他活性成分组合使用。
• A Simple Route to New Phenanthro- and Phenanthroid-Fused Thiazoles by a PIFA-Mediated (Hetero)biaryl Coupling Reaction
  作者：Isabel Moreno、Imanol Tellitu、Esther Domínguez、Raúl SanMartín

  DOI：10.1002/1099-0690(200207)2002:13<2126::aid-ejoc2126>3.0.co;2-a

  日期：2002.7

  An application of the PIFA-mediated [PIFA: phenyliodine(III) bis(trifluoroacetate)] biaryl coupling reaction is presented and extended to the formation of heterobiaryl connections. A preliminary study of the scope and limitations of this procedure was carried out in the synthesis of phenanthroids 11 from a series of phenethyl-substituted heterocycles 10. It was observed that in some cases a competitive

  提出了 PIFA 介导的 [PIFA: 苯基碘 (III) 双 (三氟乙酸酯)] 联芳基偶联反应的应用，并将其扩展到形成杂联芳基连接。在从一系列苯乙基取代的杂环 10 合成拟类化合物 11 时，对该程序的范围和局限性进行了初步研究。观察到在某些情况下发生了竞争性二聚化过程。还发现，如果芳环与 1,2-二芳基乙烷骨架稠合，则偶联步骤可以有效地扩展到更多的实例，如 23 和 30。一系列 4,5-的合成因此，进行二芳基噻唑 23a-g 以探索 PIFA 介导的非酚类偶联反应的电子要求和区域选择性。当将相同的程序应用于芳基-杂芳基噻唑 30 时，以良好的总产率获得了一系列菲类稠合的噻唑 31。据我们所知，以前没有报道过这种类型的氧化芳基-杂芳基偶联反应。(© Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002)
• [EN] SMARCA INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE SMARCA ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020251974A1

  公开（公告）日：2020-12-17

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/or polybromo-1 (PB-1) protein via ubiqitination and/or degradation by compounds. The compounds are useful in treatment of cancer.

  本发明提供了化合物、其药用可接受的组合物，以及使用这些化合物调节一个或多个SWI/SNF相关基质相关肌动蛋白依赖调节剂基因座亚家族A（SMARCA）和/或polybromo-1（PB-1）蛋白通过化合物的泛素化和/或降解的方法。这些化合物在癌症治疗中很有用。

表征谱图